Диссертация (1139777), страница 20
Текст из файла (страница 20)
et al. PET imaging with 11C-acetate inprostate cancer: a biochemical, radiochemical and clinical perspective. // Eur JNucl Med Mol Imaging, 2008; 35: 942–949.112.Oyama N., Akino H., Kanamaru H. et al. 11С-acetate PET imaging ofprostate cancer. // J Nucl Med, 2002; 43: 181–186.113.Oyama N., Miller T.R., Dehdashti F.
et al. 11С-acetate PET imaging ofprostate cancer: detection of recurrent disease at PSA relapse. // J Nucl Med,2003; 44: 549–555.114.Sandblom G., Sorensen J., Lundin N. et al. Positron emission tomographywith 11C-acetate for tumor detection and localization in patients with prostatespecific antigen relapse after radical prostatectomy. // Urology, 2006; 67: 996–1000.115.Nanni C., Castellucci P., Farsad M. et al.
11С/18F-choline PET or11С/18F-acetate PET in prostate cancer: may a choice be recommended? // Eur J123Nucl Med Mol Imaging, 2008; 35: 253–263.116.Kotzerke J., Volkmer B.G., Glatting G. et al. Individual comparison of[11C]acetate and of [11C]choline PET for detection of metastases of prostatecancer. // Nuklearmidizin, 2003; 42(1): 25–30.117.Nunez R., Macapinlac H.A., Yeung H.W. et al. Combined 18F-FDG and11C-methionine PET scans in patients with newly progressive metastatic prostatecancer. // J Nucl Med, 2002; 43: 46–55.118.Shiiba M., Ishihara K., Kimura G.
et al. Evaluation of primary prostatecancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. // Ann NuclMed, 2012; 26(2): 138–145.119.Stanbrough M., Bubley G.J., Ross K. et al. Increased expression of genesconverting adrenal androgens to testosterone in androgen-independent prostatecancer. // Cancer Res, 2006; 66: 2815–2825.120.Chen C.D., Welsbie D.S., Tran C.
et al. Molecular determinants ofresistance to antiandrogen therapy. // Nat Med, 2004; 10: 33–39.121.Larson S.M., Morris M., Gunther I. et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosteroneversus18F-FDGinpatientswithprogressive,metastatic prostate cancer. // J Nucl Med, 2004; 45: 366–373.122.Dehdashti F., Picus J., Michalski J.M. et al. Positron tomographicassessment of androgen receptors in prostatic carcinoma.
// Eur J Nucl Med MolImaging, 2005; 32: 344–350.123.Scher I., Beer T.M., Higano C.S. et al. Antitumour activity of MDV3100 incastration-resistant prostate cancer: a phase 1-2 study. // Lancet, 2010; 375:1437–1446.124.Mankoff D.A., Shields A.F., Krohn K.A. PET imaging of cellularproliferation. // Radiol Clin North Am, 2005; 43: 153–167.125.CouturierO.,LeostF.,CamponeM.etal.Is3’-deoxy-3’-[18F]fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after[18F]-FDG? // Bull Cancer, 2005; 92: 789–798.126.Nimmagadda S., Shields A.F. The role of DNA synthesis imaging in cancer124in the era of targeted therapeutics.
// Cancer Metastasis Rev, 2008; 27: 575–587.127.Kukuk D., Reischl G., Raguin O. et al. Assessment of PET tracer uptake inhormone-independent and hormone-dependent xenograft prostate cancer mousemodels. // J Nucl Med, 2011; 52: 1654–1663.128.Oyama N., Ponde D., Dence C. et al. Monitoring of therapy inandrogendependent prostate tumor model by measuring tumor proliferation.
// JNucl Med, 2004; 45: 519–525.129.Oyama N., Hasegawa Y., Kiyono Y. et al. Early response assessment inprostate carcinoma by 18F-fluorothymidine following anticancer therapy withdocetaxel using preclinical tumor models. // Eur J Nucl Med Mol Imaging, 2011;38: 81–89.130.Fanucchi M.P., Leyland-Jones R., Young C.W. et al.
Phase I trial of 1-(2’-deoxy-2’-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU). // CancerTreat Rep, 1985; 69: 55–59.131.Shields A.F. Positron emission tomography measurement of tumormetabolism and growth: its expanding role in oncology. // Mol Imaging Biol,2006; 8: 141–150.132.Jadvar H., Yap L.I., Park R. et al.
[18F]-2’-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18FFMAU) in prostate cancer: initial preclinicalobservations. // Mol Imaging, 2012; 11(5): 426–432.133.Heston, W. Bedeuteng des prostataspezifischen membranantigens (PSMA).// Urologe Ausgabe A, 1996; 35(5): S. 400–407.134.Gregorakis A.K., Homes E.H., Murphyet G.P. Prostate-specific membraneantigen: current and future utility. // Seminars in Urologic Oncology, 1998; 16: 2–12.135.Silver, D.A.
Prostate-specific membrane antigen expression in normal andmalignant human tissues. // Clinical Cancer Research, 1997; 3: 81–85.136.Власова О.П. Новые радиофармпрепараты для диагностики и леченияметастатического рака предстательной железы на основе ингибиторовпростатспецифического мембранного антигена / О.П. Власова, К.Э. Герман,125В.В.
Крылов [и др.] // Вестник Российской академии медицинских наук. –2015. – №3. – С. 360–365.137.Afshar-Oromieh A., Malcher A., Eder M. et al. PET imaging with a[68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer:biodistribution in humans and first evaluation of tumour lesions. // Eur J NuclMed Mol Imaging, 2013; 40: 486–495.138.Ceci F., Uprimny C., Nilica B. et al. 68Ga-PSMA PET/CT for restagingrecurrent prostate cancer: which factors are associated with PET/CT detectionrate? // Eur J Nucl Med Mol Imaging, 2015; 42(8): 1284–1294.139.Hellwig D., Moosbauer J., Eilles C.
[Ga-68-PSMA PET/CT for prostatecancer]. // Aktuelle Urol, 2014; 45(6): 457–63.140.Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and18F- or 11C-choline. // J Nucl Med, 2011; 52: 81–89.141.Scher B., Seitz M., Albinger W. et al. Value of 11C-choline PET andPET/CT in patients with suspected prostate cancer. // Eur J Nucl Med MolImaging, 2007; 34: 45–53.142.Giovacchini G., Picchio M., Coradeschi E. et al. [(11)C]choline uptakewith PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels,tumour stage and anti-androgenic therapy.
// Eur J Nucl Med Mol Imaging, 2008;35: 1065–1073.143.Martorana G., Schiavina R., Corti B. et al. 11C-choline positron emissiontomography/computerized tomography for tumor localization of primary prostatecancer in comparison with 12-core biopsy. // J Urol, 2006; 176: 954–960.144.Schmid D.T., John H., Zweifel R.
et al. Fluorocholine PET/CT in patientswith prostate cancer: initial experience. // Radiology, 2005; 235: 623–628.145.Yoshida S., Nakagomi K., Goto S. et al. 11C-choline positron emissiontomography in prostate cancer: primary staging and recurrent site staging. // UrolInt, 2005; 74: 214–220.126146.Yamaguchi T., Lee J., Uemura H. et al. Prostate cancer: a comparativestudy of 11C-choline PET and MR imaging combined with proton MRspectroscopy. // Eur J Nucl Med Mol Imaging, 2005; 32: 742–748.147.Souvatzoglou M., Weirich G., Schwarzenboeck S.
et al. The Sensitivity of[11C]Choline PET/CT to Localize Prostate Cancer Depends on the TumorConfiguration. // Clin Cancer Res, 2011; 17: 3751–3759.148.Beheshti M., Imamovic L., Broinger G. et al. 18F choline PET/CT in thepreoperative staging of prostate cancer in patients with intermediate or high riskof extracapsular disease: a prospective study of 130 patients. // Radiology, 2010;254: 925–33.149.Castellucci P., Fuccio C., Nanni C.
et al. Influence of trigger PSA and PSAkinetics on 11C-Choline PET/ CT detection rate in patients with biochemicalrelapse after radical prostatectomy. // J Nucl Med, 2009; 50(9): 1394–1400.150.Giovacchini G., Picchio M., Coradeschi E. et al. Predictive factors of [11C]Choline PET/CT in patients with biochemical failure after radical prostatectomy.// Eur J Nucl Med Mol Imaging, 2010; 37: 301–309.151.Rodado-Marina S., Coronado-Poggio M., García-Vicente A.M. et al.Clinical utility of (18) F-fluorocholine positron-emission tomography/computedtomography (PET/CT) in biochemical relapse of prostate cancer after radicaltreatment: results of a multicentre study.
// BJU Int, 2015; 115(6): 874–83.152.Cimitan M., Evangelista L., Hodolic M. et al. Gleason score at diagnosispredicts the rate of detection of 18F-choline PET/CT performed whenbiochemical evidence indicates recurrence of prostate cancer: experience with1,000 patients.
// J Nucl Med, 2015; 56(2): 209–15.153.Гранов А.М. Первый опыт применения позитронной эмиссионнойтомографии с 11С-Холином при раке предстательной железы (РПЖ) / А.М.Гранов, Л.А. Тютин, Д.В. Рыжкова [и др.] // Вопросы онокологии. – 2013. –№4. – С. 460–464.127154.de Jong I.J., Pruim J., Elsinga P.H. et al. Visualization of prostate cancerwith 11C-choline positron emission tomography. // Eur Urol, 2002; 42: 18–23.155.de Jong I.J., Pruim J., Elsinga P.H.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
